Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$5 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-277.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.8
Industry P/E
--
EV/EBITDA
-3.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-6.7
Face value
--
Shares outstanding
2,151,607
CFO
$-61.07 Mln
EBITDA
$-64.35 Mln
Net Profit
$-65.07 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
HCW Biologics Inc (HCWB)
| -72.4 | -50.4 | -72.4 | -97.6 | -83.2 | -- | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
HCW Biologics Inc (HCWB)
| -94.6 | -63.3 | -36.0 | -17.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
HCW Biologics Inc (HCWB)
|
0.3 | 5.4 | 0.4 | -12.1 | -2,438.2 | -- | -- | 2.8 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include... HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer. The company has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida. Address: 2929 North Commerce Parkway, Miramar, FL, United States, 33025 Read more
Founder, CEO, Director & Secretary
Dr. Hing C. Wong Ph.D.
Founder, CEO, Director & Secretary
Dr. Hing C. Wong Ph.D.
Headquarters
Miramar, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of HCW Biologics Inc (HCWB) is $0.27 (NASDAQ) as of 02-Apr-2026 19:02 EDT. HCW Biologics Inc (HCWB) has given a return of -83.15% in the last 3 years.
Since, TTM earnings of HCW Biologics Inc (HCWB) is negative, P/E ratio is not available.
The P/B ratio of HCW Biologics Inc (HCWB) is 2.80 times as on 31-Mar-2026, a 30 discount to its peers’ median range of 3.98 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.01
|
-0.07
|
|
2023
|
-0.05
|
0.09
|
|
2022
|
-0.13
|
0.05
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of HCW Biologics Inc (HCWB) are Rs 17.80 and Rs 0.25 as of 05-Apr-2026.
HCW Biologics Inc (HCWB) has a market capitalisation of $ 5 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in HCW Biologics Inc (HCWB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.03
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.